Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 108 for “"Triple Negative Breast Cancer (TNBC)"”.
-
Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
Breast cancer is the most common form of female malignancy globally. There are several subtypes of breast cancers including Triple-negative breast cancer (TNBC), which is mainly characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal …
-
The role of DNA damage associated microRNAs in enhancing the chemotherapeutic responses in triple negative breast cancer (TNBC)
Triple negative breast cancer (TNBC) is a heterogeneous aggressive type of mammary tumour which lacks a definite tailored therapeutic approach, consequently limiting treatment options to chemotherapeutic agents. Doxorubicin has demonstrated significant efficacy in the treatment of TNBC although …
-
Next-Generation version of pseudomonas exotoxin a based immunotoxins with reduced immunogenicity for triple negative breast cancer (TNBC) treatment
Breast cancer continues to have the highest mortality rate in comparison to other cancer types, with approximately 19.4 million women aged 15 years and older living at risk of being diagnosed with breast cancer in South Africa. Triple-negative breast cancer (TNBC) subtype, which is mainly …
-
Identification of the Phosphatase NUDT5 as a Target for the Treatment of Triple Negative Breast Cancer
<p>Abstract</p> <p><strong>Background</strong>: Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer, characterized by the absence of estrogen receptor (ER) and progesterone receptor (PR) expression, as well as the lack of overexpression of the human epidermal growth …
-
VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy
<p>Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly …
-
Molecular Mechanisms for the Angiotensin-(1-7)-Mediated Inhibition of Metastatic Triple Negative Breast Cancer
Approximately 40,000 women in the U.S. die from breast cancer annually. An estimated 15% of all breast cancers are triple negative, wherein tumors lack estrogen receptor and progesterone receptor expression and possess unamplified human epidermal growth factor receptor 2 (HER2) levels, contributing …
-
A Novel Drug Delivery System Incorporates a Functional Composite Scaffold Derived from Taxifolin with Potential Cytotoxic and Anticancer Effects on Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is characterised by its aggressive nature and poor prognosis. This study examines the anticancer properties of the flavonoid taxifolin and its cytotoxic and genotoxic effects on triple-negative breast cancer (TNBC) and blood cells from healthy individuals and …
-
A Novel Drug Delivery System Incorporates a Functional Composite Scaffold Derived from Taxifolin with Potential Cytotoxic and Anticancer Effects on Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is characterised by its aggressive nature and poor prognosis. This study examines the anticancer properties of the flavonoid taxifolin and its cytotoxic and genotoxic effects on triple-negative breast cancer (TNBC) and blood cells from healthy individuals and …
-
REGULATION OF C-MET RECEPTOR TYROSINE KINASE SIGNALING BY ANGIOTENSIN-(1-7) IN TRIPLE NEGATIVE BREAST CANCER
Breast cancer remains a devastating disease, negatively impacting the lives of many women worldwide. In the United States, 40,450 women succumbed to breast cancer in 2015, with an estimated 247,000 new cases being diagnosed in 2016. Approximately 15% of all breast cancer cases will be classified as …
-
Functional Regulation of Yap By Aurora A Kinase In Triple-Negative Breast Cancer
… modulation. Considering the role of YAP in cancers, this protein has emerged as a key node in malignancy development. In this study, we determined that Aurora A kinase acts as a positive regulator for YAP-mediated transcriptional machinery. Specifically, YAP associates with Aurora A …
-
Evaluation of Peptides and Peptide–Doxorubicin Conjugates Designed and Synthesized for Targeting Triple-Negative Breast Cancer via Cell-Surface Receptors
… ligand-targeted drug delivery. Among different breast cancers, treatment of the triple-negative breast cancer (TNBC) subtype has been particularly challenging, largely due to the absence of a well-defined biomarker to exploit for targeted drug delivery. This has substantially limited the number …
-
INTEGRATIVE GENOMICS UNVEILS TRANSCRIPTION FACTOR ROLES IN CELLULAR FATEAND SPATIALLY RESOLVED TRIPLE-NEGATIVE BREAST CANCER IMMUNITY CAPACITY
… cell fate decisions. The second project examines triple-negative breast cancer (TNBC), characterized by its aggressiveness and treatment challenges due to tumor heterogeneity. We propose a novel clinical workflow combining spatial transcriptomics, RNA sequencing, and Immunohistochemistry to …
-
CHARACTERISATION OF A NOVEL SMALL MOLECULE INHIBITOR FOR IMMUNE ACTIVATION IN TRIPLE NEGATIVE BREAST CANCER
Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with poor prognosis and limited treatment options. Our group has previously identified a novel small molecule inhibitor, CHL-4, whose anti-tumour effects function through Lyn kinase, a member of the Src family …
-
Dual Inhibition of the PI3K/Akt and MEK5/ERK5 Pathways for the Treatment of Breast Cancer
<p>Breast cancer is a heterogeneous disease state with several challenging frontiers. In particular, aberrations in the Phosphoinositide-3-kinase (PI3K) and Mitogen Activated Protein Kinase (MAPK) pathways have been linked to increased breast cancer proliferation and survival. It has been proposed …
-
NANOPARTICLE BASED MULTI-MODAL THERAPIES AGAINST TRIPLE-NEGATIVE BREAST CANCER
Triple-negative breast cancer (TNBC) is a highly metastatic and lethal form of breast cancer that lacks surface markers commonly targeted by hormone or immunotherapies. Silver nanoparticles (AgNPs) have exhibited a selective toxicity against TNBC cell lines at concentrations that are not lethal to …
-
Evaluating Phosphatidylinositide as Lipid Biomarkers for Hyperglycemia-related Triple-negative Breast Cancer Aggressiveness
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, marked by limited treatment options and poor patient outcomes. Clinical and epidemiological studies suggest that systemic metabolic conditions, particularly high blood glucose associated with Type 2 Diabetes, may …
-
PRUNE_1 INVOLMENT IN TNBC ENHANCING CANCER METABOLISM
… depend on the metabolic reprogramming of cancer cells to meet heightened energy and biosynthetic demands. Triple-Negative Breast Cancer (TNBC), characterized by the absence of hormone and HER2 receptors, exhibits high glycolytic and oxidative phosphorylation (OXPHOS) activity, contributing …
-
Development of Rational Combination Therapy With Parp Inhibitors and Kinase Inhibitors In Tnbc
… as potential targeting drugs for BRCA-deficient cancers including triple negative breast cancer (TNBC). However, it has been reported that a subgroup of patients even with BRCA mutation fails to respond to PARPi in multiple clinical trials. In this study, we identified c-Met, a tyrosine kinase, …
-
Investigation of the anti-cancer effects of rosemary (Rosmarinus Officinalis L.) extract in human breast and prostate cancer cells
Breast and prostate cancer are the most frequently diagnosed cancers in women and men respetively, in North America. Triple-negative breast cancer (TNBC) cells do not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER-2). TNBC accounts for 15% of all …
-
Localized and disease-selective drug delivery using adhesive hydrogels for treatment of locally advanced TNBC
Triple negative breast cancer (TNBC) is an aggressive form of cancer that represents 20% of invasive breast cancers, and about 15% are locally advanced at time of presentation. TNBC is negative for estrogen and progesterone receptor, as well as for HER2, and hence it is not treatable with common …
Page 1 of 6